Hagemann et al. report that NF-κB (IKKβ) inhibition, specifically in TAMs, reprograms them to an M1 cytotoxic profile (IL-12high/Arg1low/NOS2high), restores antitumor activity, and regresses advanced ovarian tumors in vivo [164]. The gene discussed is NFKB1; the disease is ovarian neoplasm.